

IN THE SPECIFICATION

Please insert the following new paragraph at the beginning of page 1.

Cross-Reference to Related Applications:

This application is a 371 of PCT/IB2003/003698, filed 18 August 2003, which claims priority from Great Britain Patent Application 0219639.2, filed 22 August 2002.

Please replace the paragraph at page 1, lines 1-5 with a new paragraph as follows:

Technical Field

The present invention relates to pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and their use in the treatment of stress-related affective disorders. The term "stress-induced affective disorder" is used herein to include any disorder associated with elevated levels of 5-HT (5-hydroxytryptamine; serotonin) resultant from newly synthesised 5-HT.

Please replace the paragraph at page 1, lines 6-8 with a new paragraph as follows:

Background of the Invention

3-Phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones of the following Formula I and their acid addition salts have been known since 1974 (see BE-A-808,958; corresponding to GB-A-1,455,687 & US-A-3,963,729):

Please replace the paragraph at page 2, lines ²³⁻³²~~21-30~~ with a new paragraph as follows:

Summary of the Invention

It has now surprisingly been found that the aforementioned problems of weight loss and hepatocyte changes can be overcome by the use of the pamoate salt instead of the hydrochloride, or other previously disclosed salt, of compounds of Formula I. These pamoate salts do not cause weight loss and the indications are that they will not cause hepatocyte changes over prolonged periods of treatment. Furthermore, it has been found that the pamoate salts of the compounds of Formula I, contrary to the known salts, are tasteless and allow the preparation of pharmaceutical compositions for the oral administration, especially in form of suspensions, syrups and the like.